BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as … – Business Wire (press release)
|
BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as …
Business Wire (press release) Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, stated, “Stem cell mobilization is used increasingly as a method of collecting hematopoietic stem cells for transplantation, forming part of the treatment regimen for certain types of … |
